Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2023 | A Phase I study of FHD-286, a novel BRG1/BRM inhibitor, in metastatic uveal melanoma

Sapna Patel, MD, from The University of Texas MD Anderson Cancer Center, discusses FHD-286, a novel orally administered compound inhibiting ATPase components of the BAF complex in metastatic uveal melanoma. Administered at escalating doses in a Phase I trial (NCT04879017 ), FHD-286 showed promising safety and tolerability profiles in 52 patients, with dysgeusia and fatigue as common adverse events. Notably, a patient in the 10 mg QD dosing cohort achieved a partial response, sustaining treatment for 16 months, and prolonged stable disease was observed. No treatment-related deaths occurred. While the recommended phase II dose is undetermined, ongoing analysis suggests FHD-286 accumulates with daily dosing. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.